clinical_validation

Las Vegas – October 15, 2026 -- SpectroChip Inc. has committed NT$3 million (about US$94,000) over five years to Kaohsiung Municipal Siaogang Hospital under a collaboration with OTC-listed PurMinds Enterprises, Inc. (PFSF) to validate point-of-care (POC) diagnostic technologies.

The funding runs generally at NT$600,000 per year and is subject to the applicable agreement and institutional procedures. It is earmarked for approved teaching and research, which may include research consumables, testing, equipment maintenance, data analysis, research personnel, training and academic exchange. The framework preserves the hospital's independence in professional, clinical, research and procurement decisions.

San Carlos – October 12, 2026 -- Noah Medical's Galaxy System robotic bronchoscopy platform achieved 100% tool-in-lesion accuracy and 100% successful navigation to small peripheral lesions in its first-in-human FRONTIER Study, according to final results published in the Official Journal of the Asian Pacific Society of Respirology.

FRONTIER Study reports diagnostic yield of 89.5% to 94.7%

The trial measured diagnostic yield at 89.5% under a strict definition and 94.7% under an intermediate definition. The results are attributed to the platform's TiLT+ Technology.

Interventional pulmonologists at Macquarie University Hospital in Sydney, Australia, conducted the study. It assessed whether the system could reach peripheral pulmonary nodules while maintaining patient safety during bronchoscopy and for up to seven days afterward.

London – September 20, 2026 -- Business Worldwide Magazine has named MyPureSkin S.A, a Swiss nutricosmetics company, to its list of the 20 Most Innovative Healthcare Companies to Watch in 2026.

Swiss firm builds clinically validated skin-health platform from Health Valley base

Founded by Edgar Brandt and Tatiana Brandt in Switzerland's Health Valley, MyPureSkin operates on the premise that skin should receive the same nutritional and scientific attention as other organs. The company now sells across Europe, North America, the Middle East, and Australia.

Proprietary Nutrigevity framework anchors product development

MyPureSkin's formulations are built around NutrigevityTM, a proprietary framework targeting three biological pillars: Structure, Signalling, and Regeneration. The framework draws on expertise from clinical medicine, plastic surgery, gynaecology, micronutrition, and skin biology.

Houston – September 20, 2026 -- Octagos has been named to TIME and Statista's World's Top HealthTech Companies of 2026 list, marking the only cardiac implantable electronic device (CIED) monitoring company recognized in either the inaugural 2025 ranking or the 2026 edition.

TIME and Statista rank Octagos among 82 AI and Data Analytics firms out of 500 global honorees

The evaluation weighted financial performance at 50%, reputation at 30%, and online engagement at 20%. Octagos received a "Very High" performance rating within the AI and Data Analytics category, one of six categories spanning the 500-company list.

Lexington, S.C. – September 14, 2026 -- ElectroWire Medical's FDA-cleared LightningWire Transseptal Puncture System has completed its first six clinical cases at Spartanburg Medical Center in Spartanburg, South Carolina, with zero complications reported.

Six procedures spanned mitral repair, LAA occlusion and pulsed field ablation

The case mix included one mitral valve repair, one left atrial appendage occlusion, and four pulsed field ablations, performed by structural interventional cardiologist Dr. Nalin Srivastava and cardiac electrophysiologist Dr. David Rodak. The team used four different transseptal introducers and two different electrosurgical generators during the cases, testing the device's compatibility with equipment already in operator inventories.

Danbury, Conn. – September 12, 2026 -- Perosphere Technologies Inc. announced that a clinical study evaluating its ClotChek point-of-care coagulometer has been published in the peer-reviewed journal Thrombosis and Haemostasis, confirming the device's ability to detect anticoagulation levels in patients on Factor Xa inhibitors apixaban and rivaroxaban.

Study confirms ClotChek detects DOAC anticoagulation at two clinical thresholds

The research measured ClotChek Clotting Time (CKCT) against anti-FXa drug levels in patients on direct oral anticoagulants, finding strong correlations when categorized by Medical Decision Limits. The device demonstrated the ability to identify clinically meaningful anticoagulation at both the >75 ng/mL and >30 ng/mL thresholds, including sensitivity at lower drug concentrations.